COMPANY

Passage Bio

HQ: Philadelphia, PA source · passagebio.com ↗ · Mid-Atlantic

Keywords: neurology gene therapy neurodegenerative diseases Frontotemporal Dementia FTD-GRN Dementia Frontotemporal C9orf72 PBFT02

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Sep 14, 2021 Trial start Phase 1/Phase 2: A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes source ↗

2028-08 (ESTIMATED) · Phase 1/Phase 2 · A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes · NCT04747431

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT04747431	A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes	Phase 1/Phase 2	Active, not recruiting	Sep 14, 2021	2028-08 (estimated)